SLS - Company ID 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $0.00 | $1.00M | $7.60M | $1.90M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $100.00K | $200.00K | $0.00 |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | - | $15.67M | $9.28M |
| SG&A |
SELLAS Life Sciences Group, Inc. reported annual revenue of $0.00 for fiscal year 2023. That is down 100.0% from $1.00M in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $12.25M |
| $12.42M |
| $13.86M |
| $12.58M |
| $11.32M |
| $9.60M |
| Operating income | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M | -$16.98M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | -$237.00K | -$17.00K |
| Net income | -$26.86M | -$30.88M | -$37.34M | -$41.30M | -$20.70M | -$16.76M |
| EPS (diluted) | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 |